For tumor cells, Jong et al. demonstrated that epidermal growth factor (EGF)-dependent activation of MAPK contributed to PD-L1 expression in lung adenocarcinoma, and inhibitors of EGFR and MAPK kinase (MEK) were able to reverse this effect [164]. This evidence concerns the gene MAP2K7 and neoplasm.